Jereme Sylvain was named Chief Financial Officer of Dexcom Inc, effective September 14, 2026. As of November 6, 2026, Dexcom Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 10, 2026 to September 14, 2026, naming 3 appointments (Form 8-K, September 14, 2026).
DEXCOM INC named a new Chief Financial Officer on Sep 14. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Dexcom Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Dexcom Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-10 to 2026-09-14. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Dexcom Inc files it.
Also on the record for Dexcom Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.49% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.02% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 12.61% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Dexcom Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Dexcom Inc and the records around it.
Dexcom Inc elsewhere on the record
Companies that share a holder
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Dexcom Inc
Get an email when Dexcom Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dexcom Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Dexcom Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dexcom Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-14 | In | Chief Financial Officer | 2026-09-14 | 8-K, 2026-09-14 | |
| 2026-09-10 | In | Director | 8-K, 2026-09-10 | ||
| 2026-09-10 | In | 8-K, 2026-09-10 |
Who leads Dexcom Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jereme Sylvain, appointed, effective 2026-09-14 (filed 2026-09-14).
- Director: Glenn S. Boehnlein, appointed (filed 2026-09-10).
New leaders reset buying decisions — get the Full Report on Dexcom Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Dexcom Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Dexcom IncEvery change, in the filing's words
Appointed: Jereme Sylvain, Chief Financial Officer, effective 2026-09-14
On September 10, 2026, the Board of Directors (the "Board") of DexCom, Inc. ("Dexcom" or the "Company") appointed Jereme Sylvain, the Company's EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.
- In connection with Mr. Sylvain's promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the "Offer Letter") providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary.
- Mr. Sylvain remains eligible to receive annual equity awards under the Company's Amended and Restated 2015 Equity Incentive Plan, to participate in the Company's Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.
Appointed: Glenn S. Boehnlein, Director
On September 10, 2026, the Board of Directors (the "Board") of DexCom, Inc. ("Dexcom" or the "Company"), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.
Appointed: Glenn S. Boehnlein
The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation Committee and the Audit Committee of the Board, effective immediately.
- Mr. Boehnlein will hold office for a term expiring at the 2027 annual meeting of Dexcom's stockholders (the "2027 Annual Meeting").
- In accordance with Dexcom's non-employee director compensation program, upon his appointment Mr. Boehnlein was granted an initial appointment equity grant of restricted stock units ("RSUs") with a fair value of $500,000, vesting annually over the three years following the date of grant, subject to Mr. Boehnlein's continued service.
- Mr. Boehnlein will also be eligible to receive the annual equity grant to non-employee directors on or around the 2027 Annual Meeting in the form of a grant of RSUs with a fair value of $347,500 for his service on the Board and committees.
- The annual award vests on the earlier of the date of the first annual stockholder meeting thereafter or one year from the date of grant, subject to continued service.
- Vesting of outstanding equity awards held by non-employee directors is accelerated in full upon a change in control of Dexcom.
Tools for this story
Each opens in a new tab, filled in for Dexcom Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.